![]() Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. ![]() Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases) and cancers. OMIDRIA must be added to irrigation solution prior to intraocular use. In clinical trials, the most common reported ocular adverse reactions at two percent or greater are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation incidence of adverse events was similar between placebo-treated and OMIDRIA-treated patients. Important Safety Information for OMIDRIA ® Systemic exposure of phenylephrine may cause elevations in blood pressure. While OMIDRIA is broadly indicated for use in cataract surgery, the post-launch outcomes cited above are not in its currently approved labeling. In post-launch studies across conventional and femtosecond laser-assisted cataract surgery, OMIDRIA has been shown to (1) prevent intraoperative floppy iris syndrome (IFIS) and iris prolapse, (2) significantly reduce complication rates (including sight-threatening cystoid macular edema and breakthrough iritis), use of pupil-expansion devices, and surgical times, (3) significantly reduce intraoperative use of the opioid fentanyl and postoperative prescription opioids, (4) enable performance of surgery and postoperative care without the use of steroids, and (5) significantly improve uncorrected visual acuity on the first day following cataract surgery. OMIDRIA also is the only NSAID-containing product FDA-approved for intraocular use. for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is the first and only FDA-approved product of its kind and is marketed in the U.S. Outside of the U.S., Omeros will receive a 15-percent royalty rate on OMIDRIA net sales throughout the applicable patent life on a country-by-country basis. The commercial milestone payment is triggered if separate payment for OMIDRIA is secured for a continuous period of at least four years. net sales until the earlier of either Januor payment of the $200-million commercial milestone, after which Omeros will receive royalties of 30 percent of U.S. In the U.S., the royalty rate will be 50 percent of U.S. Rayner will pay Omeros royalties on both U.S. Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion. Omeros also is eligible to receive an additional $200 million in a commercial milestone payment. In addition, Omeros retains and is entitled to collect the full amount of its accounts receivable outstanding as of today’s closing. Omeros received approximately $126 million in cash at closing. The transaction was completed pursuant to an Asset Purchase Agreement that was announced on December 2, 2021. , an affiliate of Rayner Surgical Group Limited. SEATTLE-( BUSINESS WIRE)-Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |